Cureline Group’s Full Range of Research Services Now Available Through Scientist.com
Cureline Group, an industry pioneer in precision and translational medicine, today announced its plans to showcase its full spectrum of research products and services on Scientist.com, the premier preclinical research marketplace for the biopharma sector. Biopharma researchers utilizing Scientist.com can now quickly and economically access essential services such as biobanking (including collection, processing, storage and retrieval of biological samples), human sample validation (including biomarker identification and verification), preclinical animal services and preclinical project management (protocol design, study execution and data analysis), histopathology, digital pathology and other lab services that are critical to accelerating drug discovery and development.
“We are excited to continue our longstanding partnership with Scientist.com, which has helped us connect with many biopharma researchers at top pharma and biotech companies,” stated Dr. Olga Potapova, Founder and CEO of the Cureline Group. “With our 20 years of translational CRO experience, we want to make it easy for any industry or academic scientist to access the many innovative tools and technologies and regulatory expertise that we’ve brought together under one roof.”
The Cureline Group, comprised of an array of companies including Cureline, Inc., Cureline BioPathology (CBP), Cureline Molecular Services (CMS), Cureline Baltic UAB, DolceRx Baltika UAB and the newly formed Memel Biotech, offers an extensive portfolio of ISO-certified, CAP-compliant preclinical research and biomarker/companion diagnostics services. Clinical expertise will be delivered by the recent strategic partnership of palleos healthcare (Germany) and Cureline. Offering clients a full-service approach can help reduce complexity and save time.
“The Cureline Group has evolved into a one-stop shop for high-quality research services in the preclinical research and biomarker/companion diagnostic spaces,” stated Kevin Lustig, PhD, Founder and CEO at Scientist.com. "We are delighted to feature their services on Scientist.com’s fast-growing, AI-powered marketplace."
About Cureline, Inc., and the Cureline Group of companies:
As a global leader in commercial biobanking and translational research services celebrating 20 years in business in 2023, we have completed over 5,000 projects for 850 clients. Cureline, Inc., (USA) together with other Cureline Group companies, is a global precision and translational medicine contract research organization (CRO) providing biobanking and HBS services in the preclinical phase and companion diagnostics development for clinical trials to the biopharmaceutical industry. Cureline Group management are experts in global regulatory affairs, custom protocol biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2021, UAB Cureline Baltic (Lithuania) is servicing our clients' needs in animal toxicology and preclinical efficacy studies in small animals with a focus on metastatic cancer, immunology and microbiota models. Starting in 2024, Memel Biotech UAB (Lithuania) will be providing GMP CDMO service for the ATMP clinical research community.
Visit http://www.cureline.com/ to learn more.
About Scientist.com
Scientist.com's mission is to empower and connect scientists worldwide. The company's AI-powered research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.
Visit Scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
About palleos healthcare GmbH
palleos healthcare is a full-service CRO with 50 highly experienced employees covering Phase I – IV drug and medical device clinical research services in central Europe. More than 10,000 patients at 300 sites were treated in various trials and indications with the results published in highly ranked journals. palleos healthcare also offers drug development consulting services for biotech and medtech companies, streamlining their early and pre-clinical development decisive milestones, allowing earlier and more efficient exit and reinvestment. As a certified partner with best-in-class players in the digital life science field (Veeva, Medidata, etc.), palleos healthcare offers cloud-based services for data management and decentralized clinical trials.
Visit www.palleos.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230725851885/en/
Contact information
Media Contact:
Olga Potapova, CEO, The Cureline Group
+1 415-468-6400 ext. 221
olga-potapova@cureline.com
Sean Preci, Sr. Director, Marketing & Content, Scientist.com
+1 858 771-3813 ext. 187
marketing@scientist.com
Heiko Bergmann, VP Sales & Strategy, palleos healthcare GmbH
+49 611 950 190 0 ext. 50
heiko.bergmann@palleos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 22:50:00 EET | Press release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 22:36:00 EET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom